摘要
卵圆孔未闭(patent foramen ovale,PFO)是一种先天性心脏病变,超过25%的成人均存在PFO。PFO可能与多种病理情况有关,包括不明原因脑卒中(cryptogenic stroke,CS)、斜卧呼吸-直立型低氧血症、减压病、偏头痛等,其诊断、评估和治疗已经越来越引起人们的重视。但是,有关其治疗方法的选择目前仍在争议中,虽然尚未得到美国食品和药物管理局(FDA)的批准,经导管封堵PFO的方法在继续。其潜在的并发症包括封堵器表面血栓形成,术后房颤、残余分流,封堵器侵蚀或穿孔等。鉴于PFO封堵术与任何心脏干预一样可能引起极严重的并发症,药物治疗似乎是安全、有效的选择。本文主要综述了PFO并发CS的药物治疗,旨在为临床医生对PFO并发CS的药物选择提供理论依据。
Patent foramen ovale（PFO） is a congenital cardiac lesion present in 25% of the adult population.Diagnosis,evaluation and treatment of PFO have attracted increasing interest as it has been suggested that PFO may be associated with various pathological conditions such as cryptogenic stroke,platypnea-orthodeoxia syndrome,decompression sickness and migraine.Management of PFO remains controversial and,although not yet approved by the U.S.Food and Drug Administration,transcatheter approach to PFO closure continues to develop.However,its potential complications include device embolization,thrombus formation,atrial arrhythmias,residual shunting and device erosion or perforation.As with any cardiac intervention,transcatheter closure may cause serious complications and drug therapy thus seems to be a safe and effective option.This paper reviews the drug therapy of PFO with cryptogenic stroke to provide a theoretical basis of its drug treatment for clinicians.
出处
《心脏杂志》
CAS
2013年第3期284-287,共4页
Chinese Heart Journal
